Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 79 citing articles:

IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression
Gilmar Gutiérrez, Jennifer Swainson, Nisha Ravindran, et al.
Psychiatry Research (2024) Vol. 340, pp. 116125-116125
Open Access | Times Cited: 2
Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial
Rodrigo P. Mello, Mariana V.F. Echegaray, Ana Paula Jesus‐Nunes, et al.
Journal of Psychiatric Research (2021) Vol. 138, pp. 576-583
Closed Access | Times Cited: 17
Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression
Sara de la Salle, Jennifer L. Phillips, Pierre Blier, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2021) Vol. 115, pp. 110507-110507
Open Access | Times Cited: 17
Transcranial magnetic stimulation and intravenous ketamine combination therapy for treatment-resistant bipolar depression: A case report
Laurent Elkrief, Olivier Payette, Jean-Nicolas Foucault, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 12
Ketamine: From Prescription Anaesthetic to a New Psychoactive Substance
Maria Rosaria Varı̀, Giovanna Ricci, Marco Cavallo, et al.
Current Pharmaceutical Design (2022) Vol. 28, Iss. 15, pp. 1213-1220
Closed Access | Times Cited: 11
Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series
Joseph Tham, André Do, Jason A. Fridfinnson, et al.
International Clinical Psychopharmacology (2022) Vol. 37, Iss. 5, pp. 206-214
Open Access | Times Cited: 11
Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression
Raymond T. Yan, Tyler Marshall, Atul Khullar, et al.
Therapeutic Advances in Psychopharmacology (2024) Vol. 14
Open Access | Times Cited: 2
IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital
Gilmar Gutiérrez, Melody J.Y. Kang, Gustavo Vázquez
Psychiatry Research (2024) Vol. 335, pp. 115865-115865
Open Access | Times Cited: 2
Convulsive therapy for psychiatric disorders
Tyler S. Kaster, Daniel M. Blumberger
Elsevier eBooks (2024), pp. 241-285
Closed Access | Times Cited: 2
Repeated subcutaneous esketamine on treatment-resistant depression: An open-label dose titration study
Fernanda Palhano-Fontes, Patrícia Cavalcanti-Ribeiro, Kaike Thiê da Costa Gonçalves, et al.
Journal of Affective Disorders (2024)
Closed Access | Times Cited: 2
Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management
Ryan Yip, Jennifer Swainson, Atul Khullar, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 9
A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: A preliminary evaluation of real world addictive potential
Brittany Chubbs, Jay Ching-Chieh Wang, Shaina Archer, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 9
Patients' recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression
Adrienne Lapidos, Daniela Lopez-Vives, Cortney E. Sera, et al.
Journal of Affective Disorders (2022) Vol. 323, pp. 534-539
Closed Access | Times Cited: 9
Esketamine for Unipolar Major Depression With Psychotic Features
Breno Souza‐Marques, Manuela Telles, Gustavo C. Leal, et al.
Journal of Clinical Psychopharmacology (2022) Vol. 42, Iss. 4, pp. 408-412
Closed Access | Times Cited: 8
Efficacy of ketamine for comorbid depression and acute or chronic pain: A systematic review
Aksharra Balachandran, Vanessa K. Tassone, Fathima Adamsahib, et al.
Frontiers in Pain Research (2022) Vol. 3
Open Access | Times Cited: 8
Blood transcriptional response to treatment-resistant depression during electroconvulsive therapy
Ifat Israel‐Elgali, Libi Hertzberg, Guy Shapira, et al.
Journal of Psychiatric Research (2021) Vol. 141, pp. 92-103
Open Access | Times Cited: 11
Ketamine-Assisted Psychotherapy Provides Lasting and Effective Results in the Treatment of Depression, Anxiety, and Post-Traumatic Stress Disorder at 3 and 6 Months: Findings from a Large Retrospective Effectiveness Study
Ryan Yermus, John Bottos, Nathan Bryson, et al.
Psychedelic Medicine (2024) Vol. 2, Iss. 2, pp. 87-95
Closed Access | Times Cited: 1
Recurrent Serotonin Syndrome After Ketamine-assisted Electroconvulsive Therapy: A Case Report and Review of the Literature
Aniruddha Deka, Emmanuel Joseph, Neha Sharma, et al.
Journal of Psychiatric Practice (2024) Vol. 30, Iss. 3, pp. 234-241
Closed Access | Times Cited: 1
Trends and characteristics in ketamine use among US adults with and without depression, 2015–2022
Kevin H. Yang, Wayne Kepner, Charles M. Cleland, et al.
Journal of Affective Disorders (2024)
Closed Access | Times Cited: 1
Ketamine for suicidality: An umbrella review
Ahmad Shamabadi, Ali Ahmadzade, Alireza Hasanzadeh
British Journal of Clinical Pharmacology (2022) Vol. 88, Iss. 9, pp. 3990-4018
Open Access | Times Cited: 6
Key considerations in the pharmacological management of treatment-resistant depression
Mani Yavi, Ioline D. Henter, Lawrence T. Park, et al.
Expert Opinion on Pharmacotherapy (2021) Vol. 22, Iss. 17, pp. 2405-2415
Open Access | Times Cited: 8
The drug liking and craving questionnaire (DLCQ) to evaluate addiction risk for ketamine and esketamine
Jay Ching-Chieh Wang, Atul Khullar, Roger S. McIntyre, et al.
Psychiatry Research Communications (2021) Vol. 2, Iss. 1, pp. 100018-100018
Open Access | Times Cited: 8
Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series
Olivier Payette, Paul Lespérance, Véronique Desbeaumes Jodoin, et al.
Journal of Affective Disorders (2023) Vol. 333, pp. 18-20
Closed Access | Times Cited: 3
Ketamine promptly normalizes excess norepinephrine and enhances dopamine neuronal activity in Wistar Kyoto rats
Stephen R. Daniels, Mostafa El Mansari, Rami Hamoudeh, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 3
Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression
Sagar V. Parikh, Jennifer L. Vande Voort, Anastasia K. Yocum, et al.
Journal of Affective Disorders (2023) Vol. 348, pp. 143-151
Closed Access | Times Cited: 3

Scroll to top